Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports

The acquired resistance of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is inevitable and heterogeneous. The strategies to overcome acquired resistance are significant. For patients with secondary T790M-positive after early generation EGFR-TKIs, osimertinib is the standard...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Yue, Feng, Yuanqing, Fu, Guihua, Jiang, Junlan, Liu, Xiaohan, Pan, Yue, Hu, Chunhong, Liu, Xianling, Wu, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020767/
https://www.ncbi.nlm.nih.gov/pubmed/35462930
http://dx.doi.org/10.3389/fphar.2022.838247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020767/
https://www.ncbi.nlm.nih.gov/pubmed/35462930
http://dx.doi.org/10.3389/fphar.2022.838247

Ejemplares similares